These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33560188)

  • 1. Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy.
    Harada TL; Uematsu T; Nakashima K; Kawabata T; Nishimura S; Takahashi K; Tadokoro Y; Hayashi T; Tsuchiya K; Watanabe J; Sugino T
    Radiology; 2021 Apr; 299(1):53-62. PubMed ID: 33560188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Kwon BR; Shin SU; Kim SY; Choi Y; Cho N; Kim SM; Yi A; Yun B; Jang M; Ha SM; Lee SH; Chang JM; Moon WK
    Radiology; 2022 Aug; 304(2):310-319. PubMed ID: 35536129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of breast edema on T2-weighted imaging for predicting sentinel lymph node metastasis and biological behavior in breast cancer.
    Xie S; Tang W; Zhang C; Wang J; Wang M; Zhou Y
    Clin Radiol; 2024 Aug; 79(8):e1003-e1009. PubMed ID: 38763808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can T2-weighted 3-T breast MRI predict clinically occult inflammatory breast cancer before pathological examination? A single-center experience.
    Uematsu T; Kasami M; Watanabe J
    Breast Cancer; 2014 Jan; 21(1):115-21. PubMed ID: 23104394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?
    Uematsu T; Kasami M; Watanabe J
    Breast Cancer; 2014 Nov; 21(6):684-92. PubMed ID: 23341125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
    Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
    Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
    Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
    Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
    Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
    Jacene HA; Youn T; DiPiro PJ; Hu J; Cheng SC; Franchetti Y; Shah H; Bellon JR; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth J; Yeh E; Overmoyer B;
    Clin Breast Cancer; 2019 Apr; 19(2):146-155. PubMed ID: 30584057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can peritumoral edema evaluated by Magnetic Resonance Imaging before neoadjuvant chemotherapy predict complete pathological response in breast cancer?
    Cakir Pekoz B; Dilek O; Koseci T; Tas ZA; Irkorucu O; Gulek B
    Scott Med J; 2023 Aug; 68(3):121-128. PubMed ID: 37161314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
    Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added Value of MRI for Invasive Breast Cancer including the Entire Axilla for Evaluation of High-Level or Advanced Axillary Lymph Node Metastasis in the Post-ACOSOG Z0011 Trial Era.
    Byon JH; Park YV; Yoon JH; Moon HJ; Kim EK; Kim MJ; You JK
    Radiology; 2021 Jul; 300(1):46-54. PubMed ID: 33904772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of MRI Assessment of Residual Peritumoral Edema in Breast Cancer Treated With Neoadjuvant Chemotherapy.
    Shigematsu H; Fujimoto M; Kobayashi Y; Yasui D; Komoto D; Matsuura N; Kuraoka K; Yoshiyama T
    J Magn Reson Imaging; 2024 May; ():. PubMed ID: 38809133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive Breast Cancer: Prognostic Value of Peritumoral Edema Identified at Preoperative MR Imaging.
    Cheon H; Kim HJ; Kim TH; Ryeom HK; Lee J; Kim GC; Yuk JS; Kim WH
    Radiology; 2018 Apr; 287(1):68-75. PubMed ID: 29315062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory breast cancer appearance at presentation is associated with overall survival.
    Balema W; Liu D; Shen Y; El-Zein R; Debeb BG; Kai M; Overmoyer B; Miller KD; Le-Petross HT; Ueno NT; Woodward WA
    Cancer Med; 2021 Sep; 10(18):6261-6272. PubMed ID: 34327874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.